Skip to main content
. Author manuscript; available in PMC: 2012 Mar 10.
Published in final edited form as: J Med Chem. 2011 Feb 15;54(5):1473–1480. doi: 10.1021/jm101520v

Table 4.

PK properties of selected compounds.a

Entry Cmax
(ng/mL)
I.V./P.O.		 Tmax
(h)
PO		 AUC
(h*ng/mL)
I.V./P.O.		 T1/2
(h)
I.V.		 CL
(mL/min/Kg)
I.V.		 Vss
(L/Kg)
I.V.		 F
(%)
P.O.
3 1540/3968 0.25 850/4311 0.72 19.6 1.0 51
9 426/430 0.5 391/755 0.63 42.6 2.42 19.2
14 1639/98 1.0 803/352 1.09 20.8 1.30 4.2
16 1035/853 0.5 1110/2410 1.46 15.0 1.16 21.6
17 -/1039 0.5 728/2068 0.99/1.31 22.9 1.08 28
a

C57BL/6 male mouse was dosed at 1 mg/kg for the intravenous (IV), 10 mg/kg for the oral (PO).